The Pompe disease treatment ‘Nexviazyme’ may become the first drug to receive the premium pricing benefit as a biobetter in Korea.

According to industry sources, Sanofi-Aventis Korea’s Nexviazyme (avalglucosidase alfa-ngpt) has completed the drug premium pricing calculation process and is soon to receive reimbursement. The drug is likely to receive reimbursement listing in the coming September.

In 2016, the government announced a preferential pricing plan for biobetters which are improved versions of biosimilars and previously approved biopharmaceuticals that contributed to the improvement of healthcare in Korea.

In consideration of how biobetters like Nexviazyme are m